Reports Q3 revenue $502M, consensus $491.74M. “QIAGEN (QGEN) delivered another solid performance in the third quarter of 2024, exceeding our goals for net sales and adjusted earnings thanks to the strong trends in our business and the resilience of our portfolio with over 85% of sales from highly recurring revenues. We are executing quarter after quarter in this challenging macro environment on delivering sales growth combined with market share gains and operational efficiency thanks to a differentiated portfolio,” said Thierry Bernard, CEO of Qiagen.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QGEN:
- Qiagen announces FDA clearance for QIAstat-Dx Meningitis/Encephalitis Panel
- QGEN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Qiagen announces FDA clearance of QIAstat-Dx Respiratory Panel Mini test
- Qiagen downgraded to Hold from Buy at HSBC
- Qiagen expands automated liquid biopsy portfolio